OpenAI buys Orchestra Bio to expand its drug development tools
OpenAI has bought Orchestra Bio, a startup whose AI agents help drug companies keep track of studies, schedules and problems. OpenAI will add the team to Rosalind, its set of AI tools for life sciences. The companies did not share the price.
OpenAI on Tuesday acquired Orchestra Bio, a four-year-old startup that makes AI software for drug companies, TechCrunch and Pharmaceutical Technology reported. Financial terms were not disclosed.
Orchestra builds AI agents that handle the details of running drug programs, from tracking finances to sorting out scheduling problems with clinical trials, TechCrunch reported. The startup had reportedly raised about $20 million as of 2025 from investors including Andreessen Horowitz, Atria and 8VC, the site said.
OpenAI said it will combine Orchestra's team and technology with Rosalind, its set of AI models and tools for life sciences research, Pharmaceutical Technology reported. Rosalind has two parts. GPT-Rosalind is a model that helps scientists reason through biology and chemistry questions. Rosalind Workbench connects that model to scientific tools and data so researchers can plan experiments and analyze results.
Pharmaceutical Technology gave an example of how Orchestra works. If a failed batch threatens to delay the start of a clinical trial, its agents figure out which tasks and deadlines are affected, gather the relevant information and compare options. People then decide what to do. The publication said that matters in a regulated industry, where qualified people, not software, are responsible for quality decisions.
OpenAI says its Rosalind customers include Moderna and Novo Nordisk, according to TechCrunch.
The deal shows how the biggest AI labs, especially OpenAI and Anthropic, are building more software for major industries like drugmaking, TechCrunch said. Startups often fear the labs will become competitors. In this case, TechCrunch said, Orchestra is being absorbed rather than crushed.
Pharmaceutical Technology said data security will shape how drug companies use the tools, since many want to keep their own data in-house.
What we know: OpenAI has bought Orchestra Bio and will fold it into its Rosalind life sciences tools.
What we don't: How much OpenAI paid, and when the combined tools will be available.
Where outlets agree TechCrunch and Pharmaceutical Technology both report that OpenAI bought Orchestra Bio, will add it to Rosalind and did not disclose terms.
Where they differ TechCrunch frames the deal as AI labs absorbing startups that might otherwise become rivals, while Pharmaceutical Technology focuses on oversight and data questions for drug development teams.